Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Taiwanese Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

1 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-04-10

Study Completion Date

2012-06-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the pharmacokinetics of single oral doses of ezogabine/retigabine and the primary metabolite (NAMR) in healthy male and female Taiwanese volunteers. Subjects will receive four separate doses of ezogabine/retigabine tablets: 50 mg, 100 mg, 200 mg and 400 mg administered once orally. Blood samples will be obtained at pre-defined timepoints over the duration of the study to determine the concentration of ezogabine/retigabine and NAMR. Safety assessments will include measurements of vital signs, collection of adverse events, clinical laboratory tests and the Columbia Suicide Severity Rating Scale.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.

NCT01332513

Epilepsy

COMPLETED PHASE1

Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects

NCT01691872

Epilepsy, Partial

WITHDRAWN PHASE1

Antiepileptic Drugs in Elderly Patients

NCT05459597

Seizure, Epileptic

RECRUITING

Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures

NCT04903314

Partial Epilepsy

RECRUITING PHASE1

Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

NCT02535091

Partial Epilepsy

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Ezogabine/retigabine (GW582892), N-\[2-amino-4(4-fluorobenzylamino)-phenyl\] carbamic acid ethyl ester, is a novel anti-epileptic compound which has been developed as an adjunctive treatment for partial onset seizures in patients with refractory epilepsy.

This is an open-label, randomized, single-center, 4-way crossover study to investigate the pharmacokinetics of single oral doses of ezogabine/retigabine and the n-acetyl metabolite of ezogabine/retigabine (NAMR) in healthy male and female Taiwanese volunteers. The study consists of a screening phase, 4 treatment periods and a follow-up visit. Subjects will receive each of the following four treatments administered in a randomized four-way crossover design: 50 mg, 100 mg, 200 mg and 400 mg ezogabine/retigabine tablets administered once orally. Serial blood samples will be obtained at pre-defined timepoints for pharmacokinetic analysis of ezogabine/retigabine and NAMR. Safety assessments will include measurements of vital signs, collection of adverse events, clinical laboratory tests and the Columbia Suicide Severity Rating Scale.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epilepsy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Period 1

A single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state

Group Type OTHER

50mg Ezogabine/retigabine

Intervention Type DRUG

A single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state

Treatment Period 2

A single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state

Group Type OTHER

100mg Ezogabine/retigabine

Intervention Type DRUG

A single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state

Treatment Period 3

A single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state

Group Type OTHER

200mg Ezogabine/retigabine

Intervention Type DRUG

A single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state

Treatment Period 4

A single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state

Group Type OTHER

400mg Ezogabine/retigabine

Intervention Type DRUG

A single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

50mg Ezogabine/retigabine

A single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state

Intervention Type DRUG

100mg Ezogabine/retigabine

A single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state

Intervention Type DRUG

200mg Ezogabine/retigabine

A single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state

Intervention Type DRUG

400mg Ezogabine/retigabine

A single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

GW582892 GW582892 GW582892 GW582892

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

A subject will be eligible for inclusion in this study only if all of the following criteria apply:

1. Male or female between 20 and 65 years of age inclusive, at the time of signing the informed consent.
2. Taiwanese ancestry defined as being born in Taiwan, having four ethnic Chinese/Taiwanese grandparents, holding a Taiwanese passport or identity papers and subject is able to speak Chinese/Taiwanese.
3. Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and 12-lead ECG. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
4. Body weight ≥ 50 kg and BMI within the range 18.5-24.9 kg/m2 (inclusive).
5. A female subject is eligible to participate if she is of:

* Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea \[in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) \> 40 MlU/ml and estradiol \<40 pg/ml (\<147 pmol/L) is confirmatory\]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods in Section 8.1 if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.
* Child-bearing potential and agrees to use one of the contraception methods listed in Section 8.1 for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until 1 week post-last dose of GW582892.
6. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
7. AST, ALT, alkaline phosphatase and bilirubin ≤ 1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
8. Normal ECG morphology and measurements. In particular QTcB or QTcF \< 450 msec or QTc \< 480 msec in subjects with Bundle Branch Block based on an average from three ECGs obtained over a brief recording period.

Exclusion Criteria

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

1. Subject has made a suicide attempt in the past or, in the investigator's judgment, poses a significant suicide risk. Evidence of serious suicide risk may include any history of suicidal behavior in the past 6 months and/or any suicidal ideation of type 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS).
2. A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
3. Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
4. A positive pre-study drug/alcohol screen.
5. A positive test for HIV antibody.
6. History of regular alcohol consumption within 6 months of the study defined as:

\- An average weekly intake of \>14 drinks for males or \>7 drinks for females. One drink is equivalent to 12 g of alcohol: 360 ml of beer, 150 ml of table wine or 45 ml of 80 proof distilled spirits.
7. The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
8. Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
9. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study assessments or compromise subject safety.
10. History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
11. Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
12. Pregnant females as determined by positive serum hCG test at screening or prior to dosing.
13. Lactating females.
14. Unwillingness or inability to follow the procedures outlined in the protocol.
15. Subject is mentally or legally incapacitated.
16. History of sensitivity to heparin or heparin-induced thrombocytopenia.
17. Subjects who have asthma or a history of asthma.
18. Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
19. Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.

Minimum Eligible Age

20 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

Taipei, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Study Documents

Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.